At the 2023 San Antonio Breast Cancer Symposium, Dr. Hatem Azim presented a new analysis of information from the POSITIVE trial, which found that younger women diagnosed with early-stage, hormone receptor-positive breast cancer could safely pause hormonal therapy to try to become pregnant. His new analysis looked at whether the women could use fertility preservation and assisted reproductive technologies (ART) without increasing the risk of the cancer coming back (recurrence).

Listen to the podcast to hear Dr. Azim discuss:

Scalp cooling can help people keep some or quite a lot of their hair when receiving a chemotherapy regime that can cause hair loss.

At the 2023 San Antonio Breast Cancer Symposium, Richard Paxman, CEO of Paxman Scalp Cooling, explained the updated patient assistance programs his company offers. Listen to the podcast to hear Richard explain:

Breast cancers that are lymph node-positive are usually treated with chemotherapy before surgery (neoadjuvant chemotherapy). If those cancers become lymph node-negative after neoadjuvant chemotherapy, there’s been a debate about whether to treat the nodes or not.

A new study has practicing-changing results: Nodal radiation isn’t need.

Dr. Marisa Weiss, Breastcancer.org chief medical officer and founder, and radiation oncologist, explains the findings.

Listen to the podcast to hear Dr. Weiss explain:

CDK4/6 inhibitors are used to treat both early-stage and advanced-stage hormone receptor-positive, HER2-negative breast cancer. 

The CDK4/6 inhibitors are:

At the 2023 San Antonio Breast Cancer Symposium, Dr. Stephanie Graff moderated an educational session to help people and their doctors decide on treatments after a CDK4/6 inhibitor has stopped working.

Listen to the podcast to hear Dr. Graff explain:

Living with metastatic breast cancer can bring many losses: not being able to ride bike, missing events, losing friends, just to name a few. This podcast is the audio from a special Virtual Community Meetup featuring guest moderator Kelly Grosklags.

Listen to the podcast to hear Kelly and Community members discuss:

Lobular breast cancer is cancer that starts in the lobules, the glands in the breast that produce milk. Lobular breast cancer is the second most common breast cancer, accounting for about 10% of breast cases in the United States. Lobular breast cancer doesn’t always form a lump and can spread to areas of the body different from ductal breast cancer, such as the abdominal lining or the tissue around the kidneys or the eyes.

Listen to the podcast to hear Dr. Jochelson explain:

At the European Society for Medical Oncology (ESMO) 2023 Congress Ann Partridge, MD, MPH, chaired a session titled, “Pregnancy After Breast Cancer: Is It Safe?”

Listen to the podcast to hear Dr. Partridge discuss:

At the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain, Dr. Henry Kuerer presented results from a study looking at whether some women diagnosed with early-stage triple-negative breast cancer or early-stage HER2-positive breast cancer could skip surgery if they had a pathologic complete response to chemotherapy before surgery.

Listen to the podcast to hear Dr. Kuerer explain:

At the European Society for Medical Oncology (ESMO) 2023 Congress Aditya Bardia, MD, MPH, presented results from the TROPION-Breast01 trial, which is comparing a new antibody-drug conjugate, datopotamab-deruxtecan (dato-DXd), to doctors’ choice of chemotherapy for inoperable or metastatic, hormone receptor-positive, HER2-negative breast cancer that had grown while being treated with hormonal therapy and also had been treated with chemotherapy.

Listen to the podcast to hear Dr. Bardia explain:

Finding the words to talk to children about metastatic breast cancer can be very difficult. This podcast is the audio from a special Virtual Community Meetup featuring guest moderator Kelly Grosklags.

Listen to the podcast to hear Kelly explain: